241 related articles for article (PubMed ID: 18539894)
21. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
22. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
23. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
[TBL] [Abstract][Full Text] [Related]
24. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
25. F-18 FDG PET in detecting uterine leiomyoma.
Lin CY; Ding HJ; Chen YK; Liu CS; Lin CC; Kao CH
Clin Imaging; 2008; 32(1):38-41. PubMed ID: 18164393
[TBL] [Abstract][Full Text] [Related]
26. Estrogen-dependent variations in 18F-fluorodeoxyglucose uptake in uterine leiomyomas.
Lerman H; Bar-On S; Helpman L; Even-Sapir E; Grisaru D
Int J Gynecol Cancer; 2012 Sep; 22(7):1187-91. PubMed ID: 22801027
[TBL] [Abstract][Full Text] [Related]
27. In vivo imaging of brain estrogen receptors in rats: a 16α-18F-fluoro-17β-estradiol PET study.
Khayum MA; de Vries EF; Glaudemans AW; Dierckx RA; Doorduin J
J Nucl Med; 2014 Mar; 55(3):481-7. PubMed ID: 24481026
[TBL] [Abstract][Full Text] [Related]
28. High metabolic characteristics of uterine fibroids in 18F-FDG PET/CT imaging and the underlying mechanisms.
Ma Y; Shao X; Shao X; Wang X; Wang Y
Nucl Med Commun; 2016 Nov; 37(11):1206-11. PubMed ID: 27281358
[TBL] [Abstract][Full Text] [Related]
29. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI.
Kitajima K; Murakami K; Yamasaki E; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Jul; 22(6):505-12. PubMed ID: 18670857
[TBL] [Abstract][Full Text] [Related]
30. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
31. Aberrant Hypermetabolism of Benign Uterine Leiomyoma on 18F-FDG PET/CT.
Nunes RF; Queiroz MA; Buchpiguel CA; Carvalho FM; Carvalho JP
Clin Nucl Med; 2019 Jun; 44(6):e413-e414. PubMed ID: 30985441
[TBL] [Abstract][Full Text] [Related]
32. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
33. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors.
Koyama K; Okamura T; Kawabe J; Ozawa N; Torii K; Umesaki N; Miyama M; Ochi H; Yamada R
J Nucl Med; 2003 Mar; 44(3):353-8. PubMed ID: 12621000
[TBL] [Abstract][Full Text] [Related]
35. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
36. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
[TBL] [Abstract][Full Text] [Related]
37. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals.
Seimbille Y; Rousseau J; Bénard F; Morin C; Ali H; Avvakumov G; Hammond GL; van Lier JE
Steroids; 2002 Aug; 67(9):765-75. PubMed ID: 12123788
[TBL] [Abstract][Full Text] [Related]
38. F-18 fluorodeoxyglucose uptake in leiomyomatous uterus.
Shida M; Murakami M; Tsukada H; Ishiguro Y; Kikuchi K; Yamashita E; Kajiwara H; Yasuda M; Ide M
Int J Gynecol Cancer; 2007; 17(1):285-90. PubMed ID: 17291269
[TBL] [Abstract][Full Text] [Related]
39. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
40. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
